SLC5A2 and chronic kidney disease: Network meta-analysis results showed that in patients with T2D and CKD, compared to finerenone, SGLT2 inhibitors significantly reduced the risks of KFP (HR 0.78, 95% CI 0.67–0.90; Figure 1H) and HHF (HR 0.71, 95% CI 0.55–0.92; Figure 1I), whereas SGLT2 inhibitors versus finerenone had the similar risks of MACE (HR 0.95, 95% CI 0.71–1.27; Figure 1J), nonfatal MI (HR 0.91, 95% CI 0.64–1.30; Figure 1K), nonfatal stroke (HR 0.70, 95% CI 0.35–1.39; Figure 1L), CVD (HR 1.00, 95% CI 0.78–1.29; Figure 1M), and ACD (HR 0.96, 95% CI 0.75–1.23; Figure 1N).